BioSpace News Archive

According to the current analysis of Reports and Data, the global Respiratory Care Devices Market valued at USD 18.41 Billion in 2019 and is expected to reach USD 37.04 billion by the year 2027, at a CAGR of 9.0%.

Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.

The global antibody fragments market was estimated at USD 7.2 billion in 2021 and it is expected to surpass around USD 11.89 billion by 2030, poised to grow at a CAGR of 5.73% from 2022 to 2030.

The global transcranial magnetic stimulation system market was estimated at USD 1.07 billion in 2021 and is expected to hit around USD 2.46 billion by 2030, growing at a CAGR of 9.69% from 2022 to 2030.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York.

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.

Haemonetics Corporation announced an agreement with Epic, a leading Electronic Health Record system, to offer Haemonetics’ SafeTrace Tx® blood bank information system to Epic’s global network of hospitals.

Conformis, Inc. announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.